Difference between revisions of "Waldenström macroglobulinemia - historical"
m |
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
||
| Line 48: | Line 48: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] --> | <!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] --> | ||
| − | # '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https:// | + | # '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27914971 PubMed] NCT00811733 |
=Relapsed or refractory= | =Relapsed or refractory= | ||
| Line 88: | Line 88: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] --> | <!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] --> | ||
| − | # '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https:// | + | # '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27914971 PubMed] NCT00811733 |
[[Category:Waldenström macroglobulinemia regimens]] | [[Category:Waldenström macroglobulinemia regimens]] | ||
Revision as of 18:59, 3 June 2021
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main WM regimen page to find other regimens.
3 regimens on this page
5 variants on this page
|
First-line therapy
Ofatumumab monotherapy
| back to top |
Regimen variant #1
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase II |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
4-week course
Regimen variant #2
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase II |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22, 29
5-week course
References
- GSK 110921: Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. link to original article contains protocol link to PMC article PubMed NCT00811733
Relapsed or refractory
Ofatumumab monotherapy
| back to top |
Regimen variant #1
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase II |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
4-week course
Regimen variant #2
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase II |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22, 29
5-week course
References
- GSK 110921: Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. link to original article contains protocol link to PMC article PubMed NCT00811733